EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy and safety of bevacizumab in neoadjuvant and concurrent chemoradiotherapy for refractory cervical cancer patients

Hua Yang, Shi Gao Huang, Mohan Dong, Xiaomeng Wang, JunHua He, Huyan Su, Changhao Liu, Yong Zhu, Lichun Wei, Zi Liu

Biomolecules and Biomedicine · 2024

DOI: 10.17305/bb.2024.10528 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules and Biomedicine, 2024. Verfasst von Hua Yang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China; Department of Radiation Oncology, the Fir…. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Bevacizumab, Neoadjuvant Therapy, Chemoradiotherapy. Die Arbeit wurde bisher 6-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A platinum-based concurrent chemoradiotherapy (CCRT) is the standard treatment for refractory cervical cancer (CC). However, the recurrence of disease and the occurrence of metastasis remain prevalent. We observed the long-term efficacy and safety of bevacizumab combined with neoadjuvant chemotherapy (NACT) and CCRT in refractory CC. A total of 62 patients with refractory CC were enrolled in this study from January 2016 to December 2019. The NACT regimen included bevacizumab (7.5 mg/kg), docetaxel (75 mg/m2), and cisplatin (75 mg/m2), administered tri-weekly for 2 cycles. The CCRT regimen included bevacizumab (7.5 mg/kg) and cisplatin (75 mg/m2), administered tri-weekly for 2 cycles. A dose of 45-50 Gy was prescribed for external beam radiotherapy (EBRT), while 30-35 Gy in 4-5 fractions was prescribed for brachytherapy (BT). Among the patients, 21 patients (33.9%) were at stages IIB-IIIB, 8 patients (12.9%) were at stage IIIC1, 19 patients (30.6%) were at stage IIIC2, and 14 patients (22.6%) were at stage IVB. Pelvic, para-aortic, supraclavicular, and inguinal lymph node metastases were discovered in 41 patients (66.1%). The median follow-up was 49.8 months (12.3-82.7 months). The median tumor volumes pre-treatment, after NACT, and before BT were 84.64 ± 53.15 cm3, 1.64 ± 13.15 cm3, and 0 ± 1.5 cm3, respectively. Complete clinical response (cCR) rates after NACT and EBRT were 35.5% and 66.1%, respectively. Four years after the diagnosis, the overall survival (OS) rate was 78.6%, the local region-free survival (LRFS) rate was 91.3%, the disease-free survival (DFS) rate was 70.6%, and the distant metastasis-free survival (DMFS) rate was 81.4%. A total of 29 patients (46.8%) experienced grade 3/4 hematological toxicity, 3 patients (4.8%) experienced grade 3 gastrointestinal toxicities, and none experienced grade 5 adverse events. Bevacizumab combined with NACT and CCRT significantly improved cCR and OS in refractory CC with acceptable toxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsBevacizumabNeoadjuvant TherapyChemoradiotherapyHumansFemaleMiddle AgedAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCisplatinTreatment Outcome

Substanzen

BevacizumabCisplatin

Autor:innen und Institutionen

  • Department of Radiation Oncology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China; Department of Radiation Oncology, the First Affiliated Hospital of Air Force Medical University, Xi'an, China.
  • Department of Radiation Oncology, the First Affiliated Hospital of Air Force Medical University, Xi'an, China.
  • Department of Medical Education, the First Affiliated Hospital of Air Force Medical University, Xi'an, China.
  • Department of Radiation Oncology, 986 Hospital of Air Force Medical University, Xi'an, China.
  • Tumor Diagnosis and Treatment Center, the First Hospital of Yulin, Yulin, China.
  • Department of Radiotherapy, Baoji Central Hospital, Baoji, China.

Zitieren

APA

Yang, H., Huang, S. G., Dong, M., Wang, X., He, J., Su, H., Liu, C., Zhu, Y., Wei, L., & Liu, Z. (2024). Efficacy and safety of bevacizumab in neoadjuvant and concurrent chemoradiotherapy for refractory cervical cancer patients. Biomolecules and Biomedicine. https://doi.org/10.17305/bb.2024.10528

Vancouver

Yang H, Huang SG, Dong M, Wang X, He J, Su H, et al. Efficacy and safety of bevacizumab in neoadjuvant and concurrent chemoradiotherapy for refractory cervical cancer patients. Biomolecules and Biomedicine. 2024. doi:10.17305/bb.2024.10528

BibTeX
@article{Yang2024,
  author = {Yang, Hua and Huang, Shi Gao and Dong, Mohan and Wang, Xiaomeng and He, JunHua and Su, Huyan and Liu, Changhao and Zhu, Yong and Wei, Lichun and Liu, Zi},
  title = {Efficacy and safety of bevacizumab in neoadjuvant and concurrent chemoradiotherapy for refractory cervical cancer patients},
  journal = {Biomolecules and Biomedicine},
  year = {2024},
  doi = {10.17305/bb.2024.10528}
}
Kostenlos starten →